The introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically shifted the landscape of cystic fibrosis care. This triple-combination modulator therapy targets the underlying protein defect in most patients. Consequently, clinical outcomes like lung function and quality of life have improved significantly. Many patients now consider reducing their daily treatment load. Because ETI therapy cystic fibrosis management is so effective, understanding which medications can be safely discontinued is a primary research focus.

The Impact of ETI Therapy Cystic Fibrosis on Treatment Burden

A recent Australian study by Corbett et al. explored how patients manage their treatments after starting ETI. The researchers conducted surveys and qualitative interviews with people with cystic fibrosis (PwCF). Interestingly, the results showed that a majority of patients have already ceased some medications. Patients often stop therapies like mucolytics or inhaled antibiotics to reduce their daily burden. However, these decisions are sometimes made without formal medical guidance.

Furthermore, large-scale clinical trials like the SIMPLIFY study have investigated this trend. These trials examined whether discontinuing hypertonic saline or dornase alfa is safe for those on ETI. The evidence suggests that for many stable patients, stopping these nebulized treatments does not lead to a significant decline in lung function over the short term. Therefore, clinicians are beginning to rationalize therapy for eligible individuals. Nevertheless, doctors must monitor patients closely to prevent long-term complications.

Rationalizing Care for Patients

While the reduction of treatment burden is beneficial, it requires a structured approach. Clinicians should discuss \"deprescribing\" with patients to ensure that essential therapies remain in place. Moreover, qualitative data indicate that reducing treatment time improves mental health and social participation. As more data emerge, official guidelines will likely reflect these changes in ETI therapy cystic fibrosis protocols.

Frequently Asked Questions

Is it safe to stop all other CF medications once I start ETI?

No, patients should not stop medications without consulting their medical team. While ETI is highly effective, some supportive therapies may still be necessary for certain patients to maintain lung health.

Which medications are most commonly discontinued in the era of ETI?

According to studies like SIMPLIFY, nebulized treatments such as hypertonic saline and dornase alfa are the most common candidates for discontinuation in stable patients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Corbett M et al. Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview. Intern Med J. 2026 Jun 19. doi: 10.1111/imj.70464. PMID: 42318767.

Mayer-Hamblett N, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023 Mar;11(4):329-340.

Bessone SK, et al. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study. J Cyst Fibros. 2024.